Adial Pharmaceuticals (ADIL) said Tuesday it is partnering with Boudicca Dx to progress regulatory strategy for its companion diagnostic genetic test for its lead investigational asset, AD04, a therapeutic agent for the treatment of Alcohol Use Disorder.
Boudicca will help ensure it is validated both technically and clinically per the US Food and Administration guidelines, Adial said.
The company said its companion diagnostic is intended to accompany AD04 in identifying potential patients, including recruitment for its planned phase 3 program.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments